Compare BLX & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLX | NTLA |
|---|---|---|
| Founded | 1977 | 2014 |
| Country | Panama | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1997 | 2016 |
| Metric | BLX | NTLA |
|---|---|---|
| Price | $51.92 | $13.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $20.45 |
| AVG Volume (30 Days) | 119.0K | ★ 3.1M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.26% | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,671,000.00 |
| Revenue This Year | $14.22 | N/A |
| Revenue Next Year | $9.84 | $62.75 |
| P/E Ratio | $8.26 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $31.14 | $5.90 |
| 52 Week High | $52.31 | $28.24 |
| Indicator | BLX | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 65.30 | 50.95 |
| Support Level | $43.50 | $12.55 |
| Resistance Level | N/A | $14.32 |
| Average True Range (ATR) | 1.20 | 0.76 |
| MACD | 0.27 | -0.04 |
| Stochastic Oscillator | 99.30 | 62.82 |
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.